How to master the usage and dosage of veentuzumab/besifu

Enfortumab is a new antibody-drug conjugate that plays an important role in the treatment of advanced or metastatic urothelial cancer (bladder cancer). As a representative of the combination of targeted therapy and cytotoxins, it uses antibodies to recognize tumor surface proteins and then delivers the cytotoxins into the cancer cells to achieve precise killing. Therefore, scientific mastery of usage and dosage is the key to ensuring maximum efficacy of drugs and reducing the risk of adverse reactions.

In the guidelines and instructions, the administration methods of veentuzumab are mainly divided into two types: monotherapy and combination therapy. In combination therapy, it is usually combined with the immune checkpoint inhibitor pembrolizumab (Pembrolizumab) and is used for advanced patients who have not received systemic treatment. The recommended dose is 1.25mg/kg (if the body weight is ≥100kg, the upper limit of the dose is 125mg), which should be infused intravenously over 30 minutes on the 1st and 8th day of a 21-day course of treatment. This regimen can provide sufficient drug exposure in a shorter period and create synergy with immunotherapy.

When veentuzumab is used as a single agent, the dosing cycle will vary. The commonly recommended regimen is a 28-day course of treatment, with intravenous infusion on days 1, 8, and 15, with each dose also being 1.25 mg/kg (the maximum dose for patients weighing more than 100 kg shall not exceed 125 mg). Compared with combination therapy, the frequency of single drug administration is slightly higher, but the interval is longer, which is beneficial to patient tolerance and physicians' monitoring of adverse reactions.

During the administration process, clinicians need to closely observe the individual differences and tolerance of patients. The toxicity of veentuzumab is closely related to dose, and common side effects include skin reactions, neuropathy, and increased blood sugar. Therefore, dose adjustment or dosing delay may be necessary during treatment depending on the patient's condition.

Reference: https://www.padcev.com/